Download PDF
Thromb Haemost 1987; 58(02): 758-763
DOI: 10.1055/s-0038-1645965
Original Article
Schattauer GmbH Stuttgart

Relationship Between Fibrinopeptide A and Fibrinogen/Fibrin Fragment E in Thromboembolism, DIC and Various Non-Thromboembolic Diseases

G Mombelli
The Ospedale La Carità, Locarno, and the Thrombosis Research Laboratory, University of Bern, Bern, Switzerland
,
R Monotti
The Ospedale La Carità, Locarno, and the Thrombosis Research Laboratory, University of Bern, Bern, Switzerland
,
A Haeberli
The Ospedale La Carità, Locarno, and the Thrombosis Research Laboratory, University of Bern, Bern, Switzerland
,
P W Straub
The Ospedale La Carità, Locarno, and the Thrombosis Research Laboratory, University of Bern, Bern, Switzerland
› Author Affiliations
Further Information

Publication History

Received 23 January 1987

Accepted after revision 14 April 1987

Publication Date:
27 June 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Increased fibrinopeptide A (FPA) levels have been reported in various non-thrombotic disorders, including cancer, acute myocardial infarction, liver cirrhosis and collagen vascular diseases. To investigate the significance of these findings, the present study combined the radioimmunoassay of FPA with that of fibrinogen/fibrin degradation fragment E (FgE) in the aforementioned disorders and compared the results with those observed in healthy subjects as well as in patients with thromboembolism and overt disseminated intravascular coagulation (DIC). Mean FPA and FgE in malignancy were 6.3 and 305 ng/ml, in myocardial infarction 5.6 and 98 ng/ml, in liver cirrhosis 2.7 and 132 ng/ml and in collagen vascular diseases 5.6 and 142 ng/ml. All these values were significantly higher than in healthy controls (mean FPA 1.6 ng/ml, mean FgE 49 ng/ml) but significantly lower than in thromboembolism (mean FPA 10.7 ng/ml, mean FgE 639 ng/ ml) and DIC (mean FPA 22.0 ng/ml, mean FgE 1041 ng/ml). The overall correlation between FPA and FgE was highly significant. Elowever, different disorders showed peculiar patterns in FPA, FgE and fibrinogen levels. In malignancy, a definite increase of FPA, FgE and plasma fibrinogen levels was observed. This finding probably indicates a compensated state of (intra- or extravascular) fibrin formation and lysis. Acute myocardial infarction was characterized by a high FPA to FgE ratio, which is interpreted to reflect acute thrombin generation and fibrin formation. FPA in cirrhosis was only marginally elevated with most single values within the normal range, indicating that intravascular coagulation was infrequent and unimportant in quantitative terms.

Keywords

Fibrinopeptide A - Fibrinogen/fibrin fragment E - Low-grade DIC
 

  • References

  • 1 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
    CrossrefPubMedGoogle Scholar
  • 2 Cronlund M, Hardin J, Burton J, Lee L, Haber E, Block KJ. Fibrinopeptide in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus. J Clin Invest 1976; 58: 142-151
    CrossrefPubMedGoogle Scholar
  • 3 Yudelman IM, Nossel HL, Kaplan KE, Hirsh J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978; 51: 1189-1195
    PubMedGoogle Scholar
  • 4 Peuscher FW, Cleton FJ, Armstrong L, Stoepman van Dalen EA, van Mourik JA, van Aken WG. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14
    PubMedGoogle Scholar
  • 5 Meyers TJ, Rickies FR, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood 1981; 57: 518-524
    PubMedGoogle Scholar
  • 6 Mombelli G, Roux A, Haeberli A, Straub PW. Comparison of 125I-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood 1982; 60: 381-388
    PubMedGoogle Scholar
  • 7 Mombelli G, Im Hof V, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation 1984; 69: 684-689
    CrossrefPubMedGoogle Scholar
  • 8 Coccheri S, Mannucci PM, Palareti G, Gervasoni W, Poggi M, Vigano S. Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis. Br J Haematol 1982; 52: 503-509
    CrossrefPubMedGoogle Scholar
  • 9 Owen Jr CA, Bowie E JW. Chronic intravascular coagulation and fibrinolysis (ICF) syndromes (DIC). Sem Thromb Hemostas 1977; 3: 268-290
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Gordon YB, Martin MJ, Landon J, Chaid T. The development of radioimmunoassays for fibrinogen degradation products: fragment D and E. Br J Haematol 1975; 29: 109-119
    CrossrefPubMedGoogle Scholar
  • 11 Joseph A EA, Dewbury KG, McGuiie PG. Ultrasound in the detection of chronic liver disease. Br J Radiol 1979; 52: 184-188
    CrossrefPubMedGoogle Scholar
  • 12 Cohen AS, Reynolds WE, Franklin EC, Kulka JP, Ropes ML, Shulman LE, Wallace SN. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis 1971; 21: 643-648
    PubMedGoogle Scholar
  • 13 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemat 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 14 Fischer R, Furlan M, Beck EA. An accelerated red-cell hemagglutination inhibition-immunoassay for measuring fibrinogen degradation products in human serum. Thromb Diathes Haemorrh 1971; 26: 311-314
    PubMedGoogle Scholar
  • 15 Godal HC, Abildgaard V. Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol 1966; 31: 342-350
    PubMedGoogle Scholar
  • 16 Zielinsky A, Hirsh J, Stranamanis G, Carter CJ, Gent M, Sackett DL, Hull R, Kelton JG, Powers P, Turpie AG. The diagnostic value of the fibrinogen/fibrin fragment E antigen assay in clinically suspected deep vein thrombosis. Blood 1982; 59: 346-350
    PubMedGoogle Scholar
  • 17 Ardaillou N, Yvart J, Le Bras P, Larrieu MJ. Catabolism of human fibrinogen fragment D in normal subjects and patients with liver cirrhosis. Thromb Haemostas 1980; 44: 146-149
    PubMedGoogle Scholar
  • 18 Nossel HL, Ti M. Kaplan K L, Spanondis K, Soland T, Butler V P Jr. The generation of fibrinopeptide A in clinical blood samples. Evidence for thrombin activity. J Clin Invest 1976; 58: 1136-1144
    CrossrefPubMedGoogle Scholar
  • 19 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 20 Mombelli G, Haeberli A, Rindlisbacher B, Straub PW. Extravascular catabolism of fibrinogen in effusions. Thromb Haemostas 1983; 50: 24 (Abstr)
    PubMedGoogle Scholar
  • 21 DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
    CrossrefPubMedGoogle Scholar
  • 22 Asinger RW, Mikell FL, Ellsperger J, Holges M. Incidence of left ventricular thrombosis after acute myocardial infarction. Serial evaluation by two-dimensional echocardiography. N Engl J Med 1981; 305: 297-302
    CrossrefPubMedGoogle Scholar
  • 23 Gallino A, Haeberli A, Baur HR, Straub PW. Fibrin formation and platelet aggregation with severe coronary artery disease: relationship with the degree of myocardial ischemia. Circulation 1985; 72: 27-30
    CrossrefPubMedGoogle Scholar
  • 24 Grossi CE, Moreneo AH, Rousselot LM. Studies on spontaneous fibrinolytic activity in patients with cirrhosis of the liver and its inhibition by epsilon amino caproic acid. Ann Surg 1961; 153: 383-393
    CrossrefPubMedGoogle Scholar